An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00097929
Recruitment Status : Completed
First Posted : December 2, 2004
Last Update Posted : April 7, 2017
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.